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Abstract 
Background: MMP-9-dependent proteolysis of histone H3 N-terminal tail (H3NT) is an important mechanism for 
activation of gene expression during osteoclast differentiation. Like other enzymes targeting their substrates within 
chromatin structure, MMP-9 enzymatic activity toward H3NT is tightly controlled by histone modifications such as 
H3K18 acetylation (H3K18ac) and H3K27 monomethylation (H3K27me1). Growing evidence indicates that DNA meth-
ylation is another epigenetic mechanism controlling osteoclastogenesis, but whether DNA methylation is also critical 
for regulating MMP-9-dependent H3NT proteolysis and gene expression remains unknown.
Results: We show here that treating RANKL-induced osteoclast progenitor (OCP) cells with the DNMT inhibitor 5-Aza-
2′-deoxycytidine (5-Aza-CdR) induces CpG island hypomethylation and facilitates MMP-9 transcription. This increase 
in MMP-9 expression results in a significant enhancement of H3NT proteolysis and OCP cell differentiation. On the 
other hand, despite an increase in levels of H3K18ac, treatment with the HDAC inhibitor trichostatin A (TSA) leads 
to impairment of osteoclastogenic gene expression. Mechanistically, TSA treatment of OCP-induced cells stimulates 
H3K27ac with accompanying reduction in H3K27me1, which is a key modification to facilitate stable interaction of 
MMP-9 with nucleosomes for H3NT proteolysis. Moreover, hypomethylated osteoclastogenic genes in 5-Aza-CdR-
treated cells remain transcriptionally inactive after TSA treatment, because H3K27 is highly acetylated and cannot be 
modified by G9a.
Conclusions: These findings clearly indicate that DNA methylation and histone modification are important mecha-
nisms in regulating osteoclastogenic gene expression and that their inhibitors can be used as potential therapeutic 
tools for treating bone disorders.
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Background
Bone is a dynamic tissue that undergoes continu-
ous remodeling to control skeletal regeneration and 
development [1, 2]. This remodeling process is highly 
orchestrated and tightly regulated by bone-forming 
osteoblasts and bone-resorbing osteoclasts [3–7]. 
Osteoclasts are large multinucleated cells that differ-
entiate from the fusion of mononuclear hematopoietic 
precursors upon stimulation by macrophage colony-
stimulating factor (M-CSF) and receptor activator of 
nuclear factor kappa B ligand (RANKL) [8, 9]. When 
RANKL binds to its cognate receptor RANK on osteo-
clast precursor (OCP) cell membrane, multiple signal-
ing pathways are activated to induce the expression of 
key osteoclastogenic factors [1, 10]. Elevated levels of 
these factors in OCP-induced cells trigger the expres-
sion of downstream genes for the initiation and tight 
regulation of osteoclast differentiation and function [1, 
10]. An abnormal increase in osteoclast formation and 
activity is a major pathological factor and leads to some 
bone diseases such as osteoporosis, where resorption 
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exceeds formation causing decreased bone density and 
increased bone fractures [11, 12]. Therefore, identifi-
cation and characterization of osteoclastogenic fac-
tors have a great therapeutic value for the treatment of 
bone disorders caused by excessive osteoclastic bone 
resorption.
Although a number of factors have been reported to 
be expressed in OCP-induced cells, how the timing and 
levels of their expression are regulated during the process 
of differentiation is not well understood. Nevertheless, it 
has become clear that epigenetic alterations are impor-
tant in controlling osteoclastogenic gene transcription 
as well as driving osteoclast formation and activity [13, 
14]. These epigenetic changes include DNA methylation 
at CpG dinucleotides and posttranslational modifications 
of histone tails [15–20]. Adding additional levels of com-
plexity to these epigenetic processes, our recent study 
identified an unexpected role for matrix metalloprotein-
ase 9 (MMP-9) in catalyzing H3 N-terminal tail (H3NT) 
proteolysis and conferring active expression properties to 
osteoclast-specific genes during osteoclast differentiation 
[21]. In this report, we demonstrated that the nuclear 
localization and H3NT cleaving activity of MMP-9 are 
necessary for transcription of osteoclastogenic genes in 
OCP-induced cells. Since abrogation of H3NT proteoly-
sis by MMP-9 shRNA and inhibitors resulted in defective 
osteoclastogenesis under RANKL treatment conditions, 
the role for MMP-9-dependent H3NT proteolysis in 
osteoclast differentiation was also firmly established [21]. 
Beyond these initial works, our follow-up experiments 
showed that MMP-9 enzymatic activity toward nucleo-
somal H3NTs is dependent on p300-mediated H3K18ac 
and G9a-mediated H3K27me1, thus establishing impor-
tant osteoclastogenic functions for p300 and G9a [22].
As an epigenetic signaling tool, DNA methylation is 
associated with transcriptional repression by either hin-
dering transcription factor binding or blocking active 
histone modifications to induce chromatin condensation 
[17, 23–29]. Therefore, in addition to H3NT proteolysis 
and histone modification, DNA methylation could be 
another process through which osteoclast formation and 
differentiation are regulated. Consistent with this view, 
a recent report indicated that DNA methyltransferase 
(DNMT) 3A, one of the de novo DNMTs, exerts its influ-
ence on the differentiation capacity of OCP cells by alter-
ing the expression of IRF8 [30]. It also has been proposed 
that DNA methylation changes are involved in the differ-
entiation dynamics of OCP-induced cells and stabiliza-
tion of osteoclast phenotypes [31]. Although these results 
support the functional importance of DNA methylation 
in the regulation of osteoclast differentiation, whether 
the observed effects of DNA methylation occur through 
inactivation of MMP-9-dependent H3NT proteolysis 
and osteoclastogenic gene expression has not yet been 
investigated.
Given that RANKL-induced formation of mature oste-
oclasts is epigenetically regulated, we hypothesized that 
DNMT and histone deacetylase (HDAC) inhibitors can 
generate distinct effects on MMP-9-dependent H3NT 
proteolysis and osteoclastogenic gene expression. In this 
study, we attempted to explore this possibility using iso-
lated murine bone marrow macrophages as OCP cells. 
We demonstrated that the DNMT inhibitor 5-Aza-CdR 
significantly facilitated RANKL-induced OCP cell dif-
ferentiation through CpG demethylation and transcrip-
tional activation of MMP-9 gene. Contrarily, however, 
treatment of OCP cells with the HDAC inhibitor TSA 
suppressed osteoclast differentiation. The observed 
effects were the result of TSA-mediated stimulation of 
H3K27ac that led to a decrease in H3K27me1 and thus 
MMP-9 localization at target genes. Moreover, when 
OCP cells were treated with the combination of 5-Aza-
CdR and TSA, TSA was found to exert dominant effects 
over 5-Aza-CdR.
Results
5‑Aza‑CdR stimulates MMP‑9 expression 
and osteoclastogenesis
Because DNA methylation has been implicated in regu-
latory networks controlling osteoclast differentiation 
[30–33], we decided to examine the extent to which 
DNMT inhibitors affect differentiation capacity of OCP 
cells. In our assay system, OCP cells were prepared from 
adult mouse long bone and synchronously differentiated 
into mature osteoclasts in α-minimal essential medium 
(α-MEM) supplemented with soluble recombinant 
RANKL for 0, 1, 3 and 5 days. In this setting, mononu-
clear OCP cells start fusing together to form multinuclear 
tartrate-resistant acid phosphatase (TRAP)+ osteoclasts 
after 3 days of RANKL treatment (Fig. 1a, upper panel). 
When OCP-induced cells were exposed to five differ-
ent concentrations (1, 3, 5, 10 and 20 μM) of the DNMT 
inhibitor 5-Aza-CdR, we found that 5-Aza-CdR signifi-
cantly stimulated RANKL-induced osteoclastogenesis at 
a final concentration of 5 μM (Additional file 1: Fig. S1a). 
In contrast, only a modest enhancement of OCP cell dif-
ferentiation was observed after treatment with 1, 3, 10 or 
20  μM 5-Aza-CdR. Moreover, the fact that 5-Aza-CdR 
had no effects on osteoclast viability at 5 μM concentra-
tion indicates that 5-Aza-CdR directly modulates the dif-
ferentiation potential of OCP cells (Fig. 1a, middle panel 
and Additional file 1: Fig. S1b). Additionally, 5-Aza-CdR 
treatment of MMP-9-depleted OCP-induced cells was 
unable to augment differentiation capacity, results indica-
tive of the requirement of MMP-9 for the observed action 
of 5-Aza-CdR (Fig. 1a, lower panel).
Page 3 of 14Shin et al. Epigenetics & Chromatin           (2019) 12:25 
Considering that MMP-9 plays an essential role in 
osteoclastogenesis [21, 22, 34], we next investigated the 
impact of 5-Aza-CdR treatment on MMP-9 expression. 
When total RNA was isolated and analyzed by RT-qPCR, 
we observed that treating OCP-induced cells with 5-Aza-
CdR enhanced MMP-9 expression to levels 10–25-fold 
higher than OCP-induced cells treated with vehicle con-
trol at days 1, 3 and 5 of differentiation (Fig.  1b, upper 
panel). It was also apparent in our Western blot analy-
sis of nuclear fractions from OCP-induced cells that 
MMP-9 protein levels increased in parallel with RNA 
levels after 5-Aza-CdR treatment (Fig.  1b, lower panel). 
In these Western blottings, we detected an additional 
slowly migrating minor band. This higher molecular 
weight band represents the uncleaved pro-MMP-9, and 
the nuclear level of this inactive form was also increased 
following 5-Aza-CdR treatment. In the same experiment, 
Lamin B expression levels were unchanged. Therefore, 
the increase in MMP-9 expression observed following 
5-Aza-CdR treatments is specific. These and the above-
noted results underscore the notion that 5-Aza-CdR 
treatment can up-regulate MMP-9 expression and aug-
ment osteoclastogenic potential of OCP-induced cells.
5‑Aza‑CdR decreases DNA methylation at the MMP‑9 locus 
and facilitates H3NT proteolysis
Our recent investigation established MMP-9 as a novel 
H3NT protease required for H3NT proteolysis observed 
during the process of osteoclast formation [21, 22]. Since 
5-Aza-CdR treatment of OCP-induced cells led to a sharp 
increase in MMP-9 expression (Fig.  1b), we wondered 
whether H3NT proteolysis is also affected by 5-Aza-CdR 
treatment. In order to check this possibility, we extracted 
chromatin from control and OCP-induced cells after 0, 
1, 3 or 5 days of 5-Aza-CdR treatment and analyzed by 
Western blotting with H3 C-terminal antibody. In agree-
ment with our published data, we detected a fast migrat-
ing H3 band representing H3NT proteolysis during 
osteoclast differentiation (Fig.  2a, left lane). In parallel 
experiments in which H3NT proteolysis was analyzed in 
5-Aza-CdR-treated OCP cells over the same time period, 
much higher levels of H3NT proteolysis were observed 
(Fig. 2a, middle lane). On the contrary, however, 5-Aza-
CdR treatment was no longer capable of positively 
regulating H3NT proteolysis, when MMP-9 was depleted 
in OCP-induced cells (Fig. 2a, right lane). These data are 
supportive of the idea that stimulatory effects of 5-Aza-
CdR on osteoclast differentiation pathway are dependent 
on MMP-9-dependent H3NT proteolysis.
Given the demonstrated effects of 5-Aza-CdR treat-
ment on MMP-9 expression and H3NT proteolysis, we 
also wanted to study how 5-Aza-CdR treatment affects 
DNA methylation levels of MMP-9 gene. Toward this 
end, we analyzed the DNA sequence of the MMP-9 
gene using a CpG island search program and identified 
a 316-bp-long CpG island that starts at 164950229 and 
extends up to 164950544 in the coding region of the gene 
(Fig.  2b). To examine changes in DNA methylation sta-
tus in this CpG island, we first conducted methylation-
specific PCR with DNA isolated from mock-treated or 
5-Aza-CdR-treated OCP-induced cells after converting 
all unmethylated cytosines to uracil. As shown in Fig. 2c, 
5-Aza-CdR treatment decreased the band intensity of the 
methylated CpG island and increased the band intensity 
of the unmethylated CpG island. To further confirm the 
demethylating effects of 5-Aza-CdR on the MMP-9 cod-
ing region in OCP-induced cells, DNA bisulfite sequenc-
ing was performed. Primers were designed to amplify 
16 different fragments that are located within the CpG 
island of the MMP-9 coding region (Fig. 2b). PCR prod-
ucts were then subcloned into a pGEM-T Easy vector, 
and 5 separate subclones were sequenced. In uninduced 
control cells, 16 CpG sites in the MMP-9 coding region 
were highly methylated, with overall methylation levels 
of ~ 90% (Fig. 2d, upper level). Approximately 30% reduc-
tion in methylation levels of the CpG sites was detected 
after RANKL-induced differentiation of OCP cells 
(Fig.  2d, middle level). Meanwhile, in a parallel experi-
ment in which OCP-induced cells were treated with 
5-Aza-CdR, CpG methylation levels in the MMP-9 cod-
ing region were decreased to nearly 25% (Fig.  2d, lower 
level), clearly indicating that 5-Aza-CdR is able to induce 
demethylation of the MMP-9 coding region in OCP-
induced cells.
5‑Aza‑CdR promotes MMP‑9 function at target genes
Having established the stimulatory effects of 5-Aza-CdR 
treatment on MMP-9 expression and osteoclastogenesis, 
(See figure on next page.)
Fig. 1 Effects of 5-Aza-CdR treatment on osteoclastogenesis and MMP-9 expression. a Mock-depleted (upper and middle panels) or 
MMP-9-depleted (lower panel) OCP cells were incubated with RANKL in the absence (upper panel) or presence (middle and lower panels) of 
5-Aza-dC for 0, 1, 3, or 5 days. Cells were fixed with formaldehyde, stained for TRAP and photographed under a light microscope (10 ×) (left). 
Representative images of osteoclasts are shown (Scale bar, 100 µm). TRAP-positive multinucleated cells [TRAP(+)MNCs] containing three or more 
nuclei and a full actin ring were counted as osteoclasts. b After treating OCP-induced cells as in a, the levels of MMP-9 expression were measured by 
qRT-PCR (upper panel) with primers in Methods section and Western blotting (lower panel) with MMP-9 antibody. Lamin B antibody was used as a 
loading control
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we next sought to explore whether 5-Aza-CdR treatment 
also influences H3NT proteolytic reactions at MMP-9 tar-
get genes. We recently developed a technique called ChIP 
of acetylated chromatin (ChIPac) to determine the genomic 
sites targeted for H3NT proteolysis during osteoclastogen-
esis [21]. This new method utilizes methylene blue to cross-
link chromatin and acetic anhydride to acetylate all lysine 
residues in fragmented chromatin. Intact H3NT-contain-
ing chromatin was then precipitated with anti-H3K14ac 
antibody and subjected to quantitative PCR or next-gen-
eration sequencing analysis. A reduced product in PCR or 
sequencing reactions relative to the control reactions using 
chromatin precipitated with an H3CT antibody is indica-
tive of H3NT proteolysis. During osteoclast differentia-
tion, MMP-9 mediates H3NT cleavage in promoter, coding 
region or both for target gene transcription in a gene-spe-
cific manner. Thus, we examined the levels of H3NT pro-
teolysis at Nfatc1, Lif and Xpr1 genes representing each 
H3NT-cleaved group in mock-treated or 5-Aza-CdR-
treated OCP-induced cells by ChIPac-qPCR. In agree-
ment with our published data [21, 22], RANKL treatment 
of OCP cells resulted in a rapid cleavage of H3NT in the 
P, CR, and both regions of Nfatc1, Lif and Xpr1 genes, 
respectively (Fig. 3a). Treatment of OCP-induced cells with 
5-Aza-CdR led to markedly higher levels of H3NT prote-
olysis at target genes relative to mock-treated cells (Fig. 3a). 
These results were further corroborated by the knock-
down experiments in which shRNA-mediated depletion of 
MMP-9 almost completely crippled such elevated H3NT 
proteolysis in 5-Aza-CdR-treated OCP-induced cells. Also, 
our examination of the levels of H3K18ac and H3K27me1 
confirmed that 5-Aza-CdR treatment did not have any sig-
nificant effects on these modifications (Fig. 3a). Thus, the 
observed augmentation of H3NT proteolysis could not be 
explained by a possible impact of 5-Aza-CdR treatment on 
p300 and G9a expression and their enzymatic activities. 
Fig. 2 Effects of 5-Aza-CdR treatment on MMP-9 CpG methylation and H3NT proteolysis. a Mock-depleted or MMP-9-depleted OCP-induced 
cells were cultured with or without 5-Aza-dC for 0, 1, 3 and 5 days. Chromatin was extracted, and the extent of H3NT proteolysis was analyzed 
by Western blotting with H3 C-terminal tail antibody. H2A was used as a loading control. b The sequence of the MMP-9 CpG island locus (NCBI 
accession: NC_000068, region: 164950229 to 164950544) containing the 16 CpGs that are written in bold and underlined. c Genomic DNA was 
obtained from OCP-induced cells that were grown in the presence or absence of 5-Aza-CdR for 5 days. The purified DNA molecules were subjected 
to sodium bisulfite conversion reaction and then analyzed by methylation-specific PCR of the MMP-9 CpG island. M, methylated; U, unmethylated. 
d Bisulfite sequencing analysis of the MMP-9 CpG island locus using genomic DNA prepared as in c. White circles, unmethylated CpGs; black circles, 
methylated CpGs
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For the purpose of examining whether 5-Aza-CdR treat-
ment also influences MMP-9 transactivation during oste-
oclastogenesis, we exposed OCP cells to 5-Aza-CdR and 
measured the levels of transcriptional activation of MMP-9 
target genes. Congruent to previously published data [21, 
22], Nfatc1, Lif and Xpr1 genes were effectively activated 
upon RANKL-induced osteoclast differentiation (Fig. 3b). 
When OCP-induced cells were treated with 5-Aza-CdR, 
much higher levels of Nfatc1, Lif and Xpr1 gene transcrip-
tion were evident (Fig. 3b). Since 5-Aza-CdR treatment was 
unable to enhance target gene expression upon depletion 
of MMP-9 by RNAi (Fig. 3b), MMP-9 was a critical target 
of the observed effects of 5-Aza-CdR treatment. Overall, 
these observations suggest that 5-Aza-CdR treatment has 
positive impact on accurate localization and transactive 
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Fig. 3 Effects of 5-Aza-CdR treatment on MMP-9 transactivation function. a Mock-depleted or MMP-9-depleted OCP-induced cells were cultured 
in the presence or absence of 5-Aza-CdR for 5 days and subjected to ChIPac/ChIP analysis using the antibodies indicated on the top. Precipitation 
efficiencies were determined for the promoter (P) and coding region (CR) of Nfatc1 (P-cleaved), Lif (CR-cleaved) and Xpr1 (P + CR-cleaved) genes by 
qPCR with primers used in our previous study [21, 22] and Methods section. b RT-qPCR assays were performed to determine fold changes in Nfatc1, 
Lif and Xpr1 expression in mock-depleted or MMP-9-depleted OCP-induced cells after 5 days of culture in the presence or absence of 5-Aza-CdR
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TSA inhibits osteoclast differentiation and H3NT 
proteolysis
We next wanted to test the possibility that the HDAC 
inhibitor TSA can influence RANKL-induced H3NT pro-
teolysis and OCP cell differentiation. Given the demon-
strated reliance of MMP-9 on H3K18ac for its enzymatic 
activity toward nucleosomal H3NT [21], it was reasona-
ble to expect that TSA treatment will stimulate H3K18ac 
and thus osteoclastogenesis. Surprisingly, however, our 
differentiation assays led us to discover that treatment of 
OCP cells with 20 nM TSA produces a significant inhibi-
tion in the differentiation capacity of OCP-induced cells 
(Fig. 4a, middle panel). In parallel assays, knockdown of 
MMP-9 failed to generate more pronounced effects in 
TSA-treated OCP-induced cell cultures (Fig.  4a, lower 
panel), indicating that TSA exerts its inhibitory effects 
on osteoclastogenesis in a MMP-9-dependent manner. 
Although TSA at concentrations higher than 20 nM was 
somewhat more inhibitory, the observed inhibition was 
likely due to a negative effect on the growth or viability, 
rather than the differentiation, of OCP cells (Additional 
file  2: Fig. S2). For this reason, we conducted all of the 
aforementioned assays with 20 nM TSA.
Since p300-mediated H3K18ac and G9a-mediated 
H3K27me1 are essential for MMP-9-dependent H3NT 
proteolysis [21, 22], we postulated that the observed inhi-
bition of osteoclastogenesis after TSA treatment is gener-
ated by changes in these modification processes. To check 
this possibility, soluble chromatin was prepared from the 
nuclei of control and OCP-induced cells after TSA treat-
ment for 0, 1, 3 or 5 days and subjected to Western blot 
analysis. As shown in Fig.  4b, higher levels of H3K18ac 
were retained in chromatin purified from TSA-treated 
OCP-induced cells than mock-treated control cells. Con-
trarily, TSA treatment of OCP-induced cells resulted in 
a substantial decrease in the levels of H3K27me, espe-
cially H3K27me1 and H3K27me3. The marked reduction 
in H3K27me1 caused by TSA treatment was surprising, 
because increased G9a expression was apparent from our 
Western blot analysis of TSA-treated, OCP-induced cells 
(Fig. 4b). Given that H3K27 can be both methylated and 
acetylated, a possible explanation for this observation is 
that H3K27ac becomes the dominant modification and 
blocks G9a-mediated H3K27me1 after TSA treatment. 
Consistent with this idea, we detected the hyperacetyla-
tion of H3K27 in chromatin samples from TSA-treated, 
OCP-induced cells (Fig.  4b). In the same experimental 
condition, TSA treatment did not appreciably alter p300 
expression levels (Fig.  4b), thus implying that p300 is 
dispensable for the H3K27ac reaction. p300-independ-
ency of the H3K27ac reaction was further supported by 
knockdown experiments, demonstrating that H3K27ac 
was not affected by p300 depletion in TSA-treated, OCP-
induced cells (Additional file 3: Fig. S3).
In order to determine whether TSA influences similarly 
on MMP-9 transactivation pathway, ChIPac/ChIP-qPCR 
assays were carried out, using chromatin prepared from 
mock-treated or TSA-treated OCP-induced cells. Fig-
ure 5a shows that H3NT proteolysis was enriched at the 
promoter and/or coding region of Nfatc1, Lif and Xpr1 
genes in mock-treated OCP-induced cells but largely dis-
appeared upon TSA treatment. The target genes harbor 
high levels of H3K27ac and lose H3K27me1 after 5-day 
TSA treatment, again suggesting monomethylation to 
acetylation switch at H3K27. Essentially, identical results 
were obtained when MMP-9-depleted OCP-induced 
cells were treated with TSA. The inhibitory effects of 
TSA treatment on osteoclastogenesis were also verified 
by monitoring changes in the expression of NFATc1, 
Lif and Xpr genes in mock-treated and TSA-treated 
OCP-induced cells. The observed repression appears to 
be independent of cellular MMP-9 levels, since deple-
tion of MMP-9 did not show a corresponding effect 
on the expression of the target genes tested in TSA-
treated OCP-induced cells (Fig.  5b). Collectively, these 
results indicate that TSA impairs MMP-9-dependent 
H3NT proteolysis and osteoclastogenesis by targeting 
H3K27me1-dependent function of MMP-9.
TSA exerts dominant effects in OCP‑induced cells 
co‑treated with TSA and 5‑Aza‑CdR
As an extension of the above-described studies that 
established opposite effects of 5-Aza-CdR and TSA treat-
ments on MMP-9-dependent H3NT proteolysis and 
osteoclastogenesis, it was also important to evaluate the 
effects of combined treatment with 5-Aza-CdR and TSA 
inhibitors. For this objective, we treated OCP-induced 
cells with 5 μM 5-Aza-CdR and 20 nM TSA, which are 
the concentrations exhibiting minimal effects on OCP 
cell viability (Additional files 1 and 2: Fig. S1b and S2b). 
Five days after treatment, OCP-induced cells were sub-
jected to TRAP assays to analyze changes in their differ-
entiation potential (Additional file 2: Fig. S2a). Our assays 
revealed that combined treatment with the DNMT inhib-
itor 5-Aza-CdR and HDAC inhibitor TSA significantly 
inhibited the formation of mature, multinucleated oste-
oclasts from OCP-induced cells (Fig.  6a). These effects 
were paralleled by an increase in the levels of MMP-9 
expression (Fig.  6b, left panel). Remarkably, however, 
H3NT proteolysis was completely abolished following 
a co-treatment with 5-Aza-CdR and TSA, as evidenced 
by the absence of a faster migrating H3 band in Western 
blotting (Fig. 6b, right panel). Moreover, and as shown in 
Fig. 7a, ChIPac and ChIP assays in 5-Aza-CdR/TSA-co-
treated OCP-induced cells showed that NFATc1, Lif and 
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Fig. 4 Effects of TSA treatment on osteoclastogenesis and H3K27me1. a Mock-depleted or MMP-9-depleted OCP-induced cells were grown with or 
without TSA for 0, 1, 3 and 5 days and analyzed by TRAP staining (left panel) and total counting (right panel). b Mock-depleted or MMP-9-depleted 
OCP-induced cells were cultured as in (a), and chromatin was extracted and analyzed by Western blotting with the antibodies indicated on the left
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Xpr1 genes harbor high levels of H3K18ac, H3K27me1 
and cleaved H3 protein in the P and/or CR regions. The 
observed enrichment of H3K27me1 and H3NT cleav-
age largely disappeared after combined treatment with 
5-Aza-CdR and TSA. Since an increase in H3K27ac 
was observed following 5-Aza-CdR and TSA treatment, 
these results support the dominant action of TSA over 
5-Aza-CdR in regulating MMP-9 target gene pathways 
necessary for proficient osteoclast differentiation. In fact, 
consistent with this concept, our RT-qPCR analyses dem-
onstrated that 5-Aza-CdR and TSA treatments of OCP-
induced cells caused two- to fivefold decreases in the 
expression of NFATc1, Lif and Xpr1 genes (Fig. 7b).
Discussion
Our recent investigation revealed that MMP-9 is the pro-
tease responsible for catalyzing H3NT proteolysis and 
activating genes encoding master regulators of osteo-
clastogenesis in response to RANKL treatment [21]. We 
also established H3K18ac and H3K27me1 as prerequi-
site marks for the recruitment and enzymatic activity of 
MMP-9 toward H3NT at target genes [21, 22]. However, 
nothing is known about the influence of DNA methyla-
tion on MMP-9-dependent H3NT proteolysis and gene 
activation reactions in OCP-induced cells. Since a large 
body of evidence links DNA methylation to gene silenc-
ing [17, 24, 35, 36], we hypothesized that DNA meth-
ylation attenuates H3NT proteolysis and that such an 
effect is associated with inhibition of osteoclast differ-
entiation. The current study supports this hypothesis 
by showing that treatment of OCP-induced cells with 
the DNMT inhibitor 5-Aza-CdR stimulates MMP-9-de-
pendent H3NT proteolysis and augments the expres-
sion of a group of genes, whose products are critical for 
the formation of multinucleated osteoclasts and their 
bone-resorbing activities. Mechanistically, exposure 
of OCP-induced cells to 5-Aza-CdR enhances MMP-9 
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Fig. 5 Effects of TSA treatment on MMP-9 transactivation function. a Mock-depleted or MMP-9-depleted OCP-induced cells were cultured in the 
presence or absence of TSA for 5 days and analyzed by ChIPac/ChIP-qPCR. b Mock-depleted or MMP-9-depleted OCP-induced cells were treated 
with TSA as in a, and relative expression levels of Nfatc1, Lif and Xpr1 genes were determined by qRT-PCR
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differentiation conditions. Also consistent with its previ-
ously demonstrated function in osteoclastogenesis [21, 
22], MMP-9-dependent H3NT proteolysis in 5-Aza-
CdR-treated OCP-induced cells significantly increased 
the number of differentiated osteoclasts and activated 
transcription of osteoclastogenic genes. To the best of 
our knowledge, this is the first report to demonstrate that 
DNA methylation is one of the mechanisms modulating 
MMP-9 expression during osteoclast differentiation and 
that 5-Aza-CdR-induced MMP-9 production is associ-
ated with the activation of osteoclastogenic transcription 
pathways.
Since MMP-9 requires H3K18ac for its enzymatic 
activity toward H3NT [21, 22], HDAC inhibitors were 
also thought to be effective in blocking H3NT proteolysis 
and osteoclastogenesis. With this expectation, the HDAC 
inhibitor TSA has also been tried in our assays. It was, 
however, somewhat surprising to see that the addition 
of TSA to OCP-induced cell culture does not stimulate, 
but rather inhibits MMP-9-dependent H3NT prote-
olysis in OCP-induced cells. In addition, TSA treatment 
substantially increased the levels of H3K27ac, correlated 
with low levels of H3K27me1 and osteoclast differentia-
tion. These results strongly argue that TSA targets HDAC 
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Fig. 6 Effects of TSA and 5-Aza-CdR co-treatment on osteoclastogenesis. a OCP-induced cells were treated with the combination of 5-Aza-CdR and 
TSA (lower panel) or DMSO control (upper panel) for 0, 1, 3 and 5 days and stained for TRAP. b OCP-induced cells were treated as in a, and changes 
in MMP-9 expression were analyzed by RT-qPCR (left panel) and Western blot (right panel). Chromatin was also isolated and analyzed by Western 
blotting to assess the effects of the combined treatment on H3NT proteolysis (right panel)
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sequester G9a-mediated H3K27me1. In an extension of 
this initial discovery, we showed further that the presence 
of TSA in OCP cell differentiation reactions contributes 
to the inhibition of MMP-9-dependent H3NT proteolysis 
through mechanisms involving disruption of H3K27me1-
MMP-9 interaction, leading to abrogation of MMP-9 
protease activity targeting H3NTs. This observation 
highlights the importance of H3K27me1 in the regulation 
of MMP-9-dependent H3NT proteolysis and confirms 
that accurate recruitment of MMP-9 to target genes is 
vital for the control of H3NT proteolysis and RANKL-
induced osteoclastogenesis. Our findings also suggest 
that HDAC activity is a promising target for therapeutic 
interventions that involve modulating osteoclastic bone 
resorption, as HDAC inhibition by TSA will decrease the 
differentiation rate of OCP cells.
Because TSA treatment switched H3K27 modifica-
tion status from monomethylation to acetylation and 
thus interfered with the binding of MMP-9 to target 
nucleosomes, we expected Aza treatment to be inef-
fective when used together with TSA. Indeed, although 
5-Aza-CdR alone increased the differentiation capac-
ity of RANKL-treated OCP cells, the combination of 
5-Aza-CdR with TSA generated a significant impair-
ment of MMP-9-dependent transactivation and osteo-
clast differentiation. The observed inhibition coincides 
with a stable reduction in H3K27me1 and an apparent 
decrease in H3NT proteolysis, again underscoring the 
importance of G9a-mediated H3K27me1 as an early 
step necessary for RANKL-induced MMP-9-dependent 
osteoclastogenesis. Although we have mainly focused on 
5-Aza-CdR and TSA, the present study could serve as an 
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Fig. 7 Effects of TSA and 5-Aza-CdR co-treatment on MMP-9 transactivation function. After treating with the combination of 5-Aza-dC and TSA for 
5 days, OCP-induced cells were subjected to ChIPac/ChIP-qPCR (a) to measure H3NT proteolysis levels and RT-qPCR (b) to quantitate Nfatc1, Lif and 
Xpr1 expression levels
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properties shared by other DNMT and HDAC inhibitors. 
It is tempting to speculate that exposure of OCP-induced 
cells to other DNMT and HDAC inhibitors might lead to 
similar outcomes, via affecting MMP-9 activity toward 
H3NTs. Also of note, our recent analyses revealed that 
cancer cells residing in bone express and secrete a group 
of factors that stimulate differentiation and maturation 
of OCP-induced cells [37, 38]. The unbalanced gen-
eration of osteoclasts leads to a massive bone resorp-
tion and releases the growth factors stored in the bone 
matrix, promoting metastatic tumor growth. This feed-
forward vicious cycle creates a fertile microenvironment 
for cancer cell growth in bone to drive the devastating 
effects of bone destruction. DNA methylation and his-
tone acetylation are also known to function in these bone 
metastatic cancer cells [37–39]. Thus, a combination of 
5-Aza-CdR and TSA that target both OCP-induced cells 
and bone-residing metastatic cancer cells may also have 
great therapeutic value in treating osteoporosis and other 
bone-erosive diseases such as rheumatoid arthritis and 
metastasis associated with bone loss.
Conclusions
Our study demonstrates that 5-Aza-CdR treatment stim-
ulates MMP-9 protease activity targeting H3NTs and 
gene transcription by elevating MMP-9 expression levels 
in OCP-induced cells. On the other hand, TSA treatment 
interferes with MMP-9-dependent H3NT proteolysis 
because it changes H3K27me1 to H3K27ac and seques-
ters MMP-9 recruitment to target genes. These results 
suggest that 5-Aza-CdR and TSA could be used to estab-
lish distinct epigenetic states to regulate localization and 
function of MMP-9 at pro-osteoclastogenic genes.
Methods
OCP cell preparation and differentiation assay
Bone marrow cells were harvested from tibias and femurs 
of 6- to 8-week-old C57BL/6 mice as recently described 
[21, 22]. The cells were cultured in α-minimum essen-
tial medium (α-MEM) supplemented with 10% fetal 
bovine serum (FBS) and M-CSF (5 ng/ml) for 12 h. Non-
adherent cells were harvested and incubated with M-CSF 
(30 ng/ml) for 48 h. Old media were replaced with fresh 
media containing M-CSF and further cultured for 24 h. 
Floating cells were removed, and adherent cells were used 
as osteoclast precursor (OCP) cells. For differentiation 
assays, OCP cells were grown in α-MEM culture medium 
containing M-CSF (30  ng/ml) and RANKL (5  ng/ml) 
with or without 5-Aza-CdR or TSA. After being cultured 
for 0, 1, 3, or 5 days, OCP-induced cells were fixed and 
stained for tartrate-resistant acid phosphatase (TRAP) 
using an acid phosphatase leukocyte kit (Sigma) as 
recently described [21, 22]. TRAP-positive multinuclear 
cells containing three or more nuclei and a full actin ring 
were counted as osteoclasts under a light microscope.
Cell viability assay
OCP cells were seeded in 96-well plates at a density of 
0.5 × 104 and treated with 5-Aza-CdR (0–20  µm) or 
TSA (0-80 nM) for 5 days. Cell viability was assessed by 
using the MTT (3-(4,5-dimethylthyazol-2-yl)-2,5-diphe-
nyl-tetrazolium bromide) cell growth assay kit (Sigma 
Aldrich) as detailed previously [40].
Western blot analysis
Chromatin was isolated from OCP-induced cells after 
completion of 5-day mock or TSA treatment and ana-
lyzed by Western blotting with anti-H3 C-terminal, anti-
H3K18ac, anti-H3K27ac, anti-H3K27me1/H3K27me2/
H3K27me3 antibodies. Protein samples were also col-
lected from 5-day 5-Aza-CdR-treated OCP-induced 
cells, and the levels of MMP-9, p300 and G9a were deter-
mined by Western blot analysis.
RNAi, ChIPac/ChIP and RT‑qPCR
For the depletion of MMP-9 and p300, OCP cells 
were transduced with MMP-9 and p300 shRNA and 
then selected with puromycin (2  μg/ml) as previously 
described [21, 22]. ChIPac assays were performed using 
chromatin that was fixed with 10  µM methylene blue 
and acetylated with 20 mM acetic anhydride as detailed 
previously [21, 22]. H3K14ac and H3CT antibodies were 
immobilized on protein A/G-PLUS agarose and used to 
immunoprecipitate cross-linked chromatin. ChIP assays 
were conducted with H3K18ac and H3K27me1 anti-
bodies and the ChIP assay kit (Millipore) as recently 
described [21, 22]. DNA fragments were recovered from 
precipitated protein–DNA complexes using Qiagen kit 
after reversal of crosslinking at 65  °C and analyzed by 
qPCR with the primers that amplify the promoter (P) 
and coding regions (CR) of Nfatc1 (P-cleaved), Lif (CR-
cleaved) and Xpr1 (P + CR-cleaved) genes. For RT-qPCR, 
total RNA was isolated from OCP-induced cells using 
the RNeasy kit (Qiagen). After converting RNA to cDNA 
using iScript cDNA Synthesis Kit (Bio-Rad), RT-PCR 
was performed using one-step QuantiTect SYBR Green 
RT-PCR kit (Qiagen) according to the manufacturer’s 
instructions. The primers used for ChIPac and RT-qPCR 
are: Nfatc1 (P: 5′-GAA GTG GTA GCC CAC GTG AT-3′, 
5′-TCT TGG CAC CAC ATA AAC CA-3′; CR: 5′-GGG 
TCA GTG TGA CCG AAG AT-3′, 5′-GGA AGT CAG AAG 
TGG GTG GA-3′; mRNA: 5′-CGT ACC TTC CTG CCA 
ATG TT-3′, 5′-TGG TGA GCT GTT GGC TGT AG-3′), Lif 
(P: 5′-CTC TGG CTG TCC TGG AAC TC-3′, 5′-CCA GGA 
CCA GGT GAA ACA CT-3′; CR: 5′-ATC TTG TGG CTT 
TGC CAA CT-3′, 5′-AGT CCT TGC CTG TCT TTC CA-3′; 
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mRNA: 5′-TAC TGC TGC TGG TTC TGC AC-3′, 5′-TGA 
GCT GTG CCA GTT GAT TC-3′), Xpr1 (P: 5′-AGG ACC 
TTC GGA AGA GCA GT-3′, 5′-CAG CAA GCA GCT CAT 
AAC CA-3′; CR: 5′-GGT GGG TTC CAC TGA AAG AA-3′, 
5′-GGT TCC TCT GAC CAA AAG CA-3′; mRNA: 5′-CGC 
AGG TTT GCT ACA CTT CA-3′, 5′-CCT ATG TTG GAC 
ACG CTC CT-3′), MMP-9 (mRNA: 5′-CAA TCC TTG 
CAA TGT GGA TG-3′, 5′-AGT AAG GAA GGG GCC CTG 
TA-3′), p300 (mRNA: 5′-GAG GAG AGA GGC CCT GAG 
TT-3′, 5′-CGG TAA AGT GCC TCC AAT GT-3′) and G9a 
(mRNA: 5′-TGC CTA TGG TCA GCT CAG -3′, 5′-GGT 
TCT TGC AGC TTC TCC AG-3′).
Methylation‑specific PCR
Genomic DNA was isolated from mock-treated or 5-Aza-
CdR-treated OCP-induced cells using the QIAamp DNA 
Blood Mini Kit (Qiagen) and subjected to bisulfite con-
version using the EpiTect Bisulfite Kit (Qiagen). Meth-
ylation-specific PCR was performed with the converted 
DNA molecules and MMP-9 CpG island-specific prim-
ers which were designed by the Methyl Primer Express 
software. The methylation-specific primer sequences of 
MMP-9 are: MMP-9 M (5′-TCG TTA TGG TTA TAT TCG 
GGTC-3′, 5′-AAT CGA CCC ACG TCT AAA AC-3′) and 
MMP-9 U (5′-GTA TTG TTA TGG TTA TAT TTG GGT 
T-3′, 5′-AAT CAA CCC ACA TCT AAA ACACC-3′).
Bisulfite sequencing
Genomic DNA (1  μg) was modified by sodium bisulfite 
conversion reaction with the EpiTect Bisulfite Kit (Qia-
gen). The modified DNA was amplified using bisulfite 
primers, which were specific for the MMP-9 CpG island 
and designed by the Methyl Primer Express software. 
After PCR reactions, PCR products were purified with a 
Gel Extraction Kit (Qiagen) and ligated into the pGEM-T 
easy vector (Promega). Five separate clones were selected 
from mock-treated or 5-Aza-CdR-treated OCP cells 
for bisulfite sequencing analysis. The bisulfite primer 
sequences are: MMP-9 (5′-GGT TTG GTT TTT TTT GTG 
AAAT-3′, 5′-AAA AAC CAC CTT TAA AAA CCAA-3′).
Antibodies
Antibodies were used in this study are as follows: anti-
MMP-9, anti-G9a anti-H2A and anti-H3 antibodies from 
Abcam; anti-H3K14ac and anti-H3K18ac antibodies from 
Active motif; anti-H3K27ac antibody from Gene Tax; 
anti-H3K27me1, anti-H3K27me2 and anti-H3K27me3 
antibodies from EpiGentek; anti-p300 and anti-Lamin B 
antibodies from Santa Cruz Biotech.
Statistical analyses
All quantitative data are presented as mean ± stand-
ard deviation (SD). Statistical analyses of datasets were 
performed with Student’s two-tailed t test or two-way 
ANOVA followed by Bonferroni post hoc test using 
GraphPad Prism software (GraphPad Software Inc.) 
which was used for all analyses of the experiments. A P 
value < 0.05 was considered statistically significant.
Additional files
Additional file 1. Effects of increasing concentration of 5-Aza-CdR on 
OCP cell viability and differentiation. a After treating with the indicated 
concentrations of 5-Aza-CdR for 5 days, OCP-induced cells were stained 
for TRAP (left) and positive cells were counted (right). b OCP cells were 
treated with 5-Aza-CdR as in (a), and their relative viability was assessed 
by MTT assay.
Additional file 2. Effects of increasing concentration of TSA on OCP cell 
viability and differentiation. a OCP-induced cells were treated with the 
indicated concentrations of TSA for 5 days and subjected to TRAP staining 
analysis. b OCP cells were treated with TSA as in (a), and their viability was 
scored by MTT assay.
Additional file 3. Analysis of effects of p300 knockdown on H3K27ac in 
TSA-treated, OCP-induced cells. Mock-depleted or p300-depleted OCP-
induced cells were cultured for 0, 1, 3, 5 days in the presence of TSA, and 
chromatins and nuclear lysates were analyzed by Western blotting with 
H3K27ac, H3, p300 and Lamin B antibodies.
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